2 Hot Biotechnology stocks, IDRA, HEB, 04/01/2013

Posted on by
Reply

Idera Announces Clinical Development Progress in Its Autoimmune Diseases Program.

Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system.

http://www.dailystockdeals.com/topten/hot-biotechnology-stocks-idra-04-01-2013

Source: company, OxBridge Research, Daily Stock Deals

CAMBRIDGE, Mass.–(BUSINESS WIRE)–

Idera Pharmaceuticals, Inc. (IDRA) today announced that it has completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects. In addition, the Company announced that its protocol for a Phase 2 study of IMO-8400 in patients with psoriasis has received “no objection” clearance from the Competent Authority of the Netherlands. IMO-8400 is an antagonist of Toll-like receptors (TLRs) 7, 8 and 9, and is in clinical development for the treatment of autoimmune diseases.

During the first quarter of 2013, the Company completed the escalating single-dose portion of the Phase 1 trial of IMO-8400 and has now completed patient dosing in the multiple-dose portion of the trial. The multiple-dose portion of the trial involved two dose levels of IMO-8400, 0.3 and 0.6 mg/kg, and placebo, with six subjects receiving each treatment of four weekly doses. The Company expects to report top-line data from the multiple-dose portion of the trial later in the second quarter of 2013.

Source: company, OxBridge Research, Daily Stock Deals

HEB, Hemispherx Biopharma

Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, an experimental drug under clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, an experimental low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases.

Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!

Source: company, OxBridge Research, Daily Stock Deals

FMCC, FNMA, Freddie Mac, Fannie Mae, gain 60% in 2 days!

Posted on by
Reply

Penny Stocks backed by the Federal Government gain 60% in 2 days!

You could have made a whopping 60% gains on Penny Stocks backed by the Federal Government of the United States of America!

We Alerted Yesterday:

(see here) Daily Stock Deals ‏@TOP10STOCKS18 Mar

Hot Stocks to Watch: $PULS $GALE $FMCC$FNMA http://www.dailystockdeals.com/topten/stocks-to-watch-03-18-2013-puls-gale-dcth-ffn-plug-stp-gigm-gold-is-back …

We detected unusual move yesterday, volume when through the roof, some 85 million shares traded and the stock gained a health 35% today.

Fannie Mae and Freddie Mac, the two government-seized mortgage financiers, appear increasingly likely to pay billions of dollars to the U.S. Treasury, focusing attention in Washington on what should replace them.

Edward J. DeMarco, the acting regulator of the two companies, appeared before the House Financial Services Committee today and urged lawmakers to reduce or eliminate the mortgage market’s reliance on taxpayers. At the same time, a Senate panel heard testimony from the authors of an alternate plan for housing-finance reform issued in February by an independent commission.

“I have been observing a developing ‘consensus’ among private-market participants that the conforming conventional mortgage market cannot operate without the American taxpayer providing the ultimate credit guarantee for most of the market,” DeMarco said in testimony at the House hearing. “That clearly is one outcome, but I do not believe it is the only outcome that can give our country a strong housing finance system. I believe that our country, and its financial system, are stronger than that.”

Washington-based Fannie Mae (FNMA) and McLean, Virginia-based Freddie Mac have been under U.S. conservatorship since 2008 and have drawn nearly $190 billion in taxpayer aid to stay afloat during that time. Lawmakers who don’t want the companies to return to their previous status as government-sponsored enterprises, or GSEs, are becoming concerned that political momentum for winding down and replacing them could erode as the housing market rebounds and profits soar.

Sources: Fannie Mae, Freddie Mac, OxBridge Research, Daily Stock Deals, Bloomberg